Clearbridge Investments LLC lifted its position in Sanofi (NASDAQ:SNY – Get Rating) by 4.6% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 139,680 shares of the company’s stock after buying an additional 6,123 shares during the period. Clearbridge Investments LLC’s holdings in Sanofi were worth $6,988,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. Tcwp LLC bought a new stake in shares of Sanofi in the 1st quarter valued at $36,000. US Bancorp DE increased its position in shares of Sanofi by 10.1% in the 2nd quarter. US Bancorp DE now owns 85,318 shares of the company’s stock valued at $4,268,000 after buying an additional 7,809 shares in the last quarter. Veriti Management LLC increased its position in shares of Sanofi by 117.4% in the 2nd quarter. Veriti Management LLC now owns 30,775 shares of the company’s stock valued at $1,540,000 after buying an additional 16,621 shares in the last quarter. Assetmark Inc. increased its position in shares of Sanofi by 188.2% in the 2nd quarter. Assetmark Inc. now owns 37,394 shares of the company’s stock valued at $1,871,000 after buying an additional 24,420 shares in the last quarter. Finally, Ritholtz Wealth Management increased its position in shares of Sanofi by 35.2% in the 2nd quarter. Ritholtz Wealth Management now owns 18,483 shares of the company’s stock valued at $925,000 after buying an additional 4,810 shares in the last quarter. Institutional investors own 10.33% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research firms have issued reports on SNY. JPMorgan Chase & Co. increased their target price on Sanofi from €105.00 ($107.14) to €115.00 ($117.35) in a report on Monday, August 1st. StockNews.com began coverage on Sanofi in a report on Wednesday, October 12th. They set a “strong-buy” rating for the company. Barclays lowered their target price on Sanofi from €105.00 ($107.14) to €85.00 ($86.73) and set an “equal weight” rating for the company in a report on Friday, October 14th. Cheuvreux cut Sanofi from a “buy” rating to a “hold” rating in a report on Wednesday, August 24th. Finally, TheStreet cut Sanofi from a “b-” rating to a “c+” rating in a report on Thursday, September 15th. Five investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $102.88.
Sanofi Trading Down 0.0 %
Sanofi Company Profile
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
- Get a free copy of the StockNews.com research report on Sanofi (SNY)
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.